Best of ASCO - 2014 Annual Meeting

 

Welcome

Small Molecules

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.

Kyriakos P. Papadopoulos

2508

A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of the dual MET kinase/OCT2 inhibitor, OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.

Elizabeth Ruth Plummer

TPS2614

A multicenter study of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.

David S. Hong

2578

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

Alexander E. Drilon

102

A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours.

Paul L. de Souza

2585

A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).

Alexander E. Drilon

2513

A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.

Manish R. Patel

2579

A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.

Sarina Anne Piha-Paul

TPS2616

A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.

Karen Kelly

TPS2617

A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.

Ruihua Xu

2593

A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.

Anthony B. El-Khoueiry

2515

A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.

Filip Janku

2586

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

Nehal J. Lakhani

2594

A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.

Melissa Lynne Johnson

2592

A real world study of efficacy and safety with apatinib therapy in advanced neuroendocrine carcinoma patients.

Chao Chen

e14567

An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.

Lore Decoster

TPS2615

BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness.

Apurva K. Srivastava

2582

Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSé Program.

Gilles Vassal

2504

Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.

David Dai

2581

Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.

Matilda Lee

2588

Final results of a phase 1 trial of sorafenib, pemetrexed, and cisplatin in patients with advanced solid tumors.

Abeer F Alharbi

e14582

First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.

Elizabeth Ruth Plummer

2505

First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.

Jose Manuel Perez Garcia

TPS2619

First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.

Kyriakos P. Papadopoulos

2514

Inhibition of autophagy by MPT0L145, a novel PIK3C3 inhibitor, to overcome drug resistance in cancer cells.

Chun-Han Chen

e14583

Metformin activity in advanced adrenocortical carcinoma: A comparative analysis in human tumors.

Robert Alan Nagourney

e14568

Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.

Young Kwang Chae

2503

Novel small molecules induced ROS accumulation and antitumor activity based on an oxidative stress gene signature.

Andrew Asher Protter

e14575

Oral small molecule modulators of p300/CBP to reprogram cancer cells and reactivate the p53 pathway in HPV-associated carcinomas.

Ulrich Kessler

e14581

Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials.

Roman Groisberg

2590

Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.

Bin Fan

2577

Phase 1 study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors.

Sun Young Rha

TPS2620

Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.

Pui Ying Chan

2589

Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.

Filip Janku

2583

Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.

Ravi Kumar Paluri

2591

Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.

Oana C. Danciu

TPS2621

Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.

Apostolia Maria Tsimberidou

2584

Preclinical development of ciclopirox prodrug for the treatment of non-muscle invasive and muscle invasive bladder cancer.

Scott James Weir

e14576

Preclinical study on the anti-tumor effect of H1 and H2 peptide.

Wanru Hou

e14565

Resminostat plus sorafenib in hepatocellular carcinoma (HCC) as apotential new treatment approach in platelet-driven solid tumors.

Frank Hermann

e14571

Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.

Ian E. Krop

101

Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.

Sarina Anne Piha-Paul

2510

Safety and efficacy of metronomic eltrombopag prophylaxis (MEP) in the prevention of chemotherapy-induced thrombocytopenia (CIT) in cancer patients.

Francesco Iuliano

e14566

Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

Mark N. Stein

2595

Safety, dose tolerance, pharmacokinetics and pharmacodynamics study of CPX-POM in patients with advanced solid tumors.

Scott James Weir

TPS2618

Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.

Naoko Takebe

2587

Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer.

Vivek K. Kashyap

e14578

Tumor response assessment using diffusion weighted imaging (DWI) in patients with liver metastases treated with Aurora A and TORC1/2 inhibitors.

Natalie Julie Serkova

e14573

Uveal melanoma patients (pts) treated with abbv-075 (mivebresib), a pan-inhibitor of bromodomain and extraterminal (BET) proteins: Results from a phase 1 study.

Sapna Pradyuman Patel

e14585

Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.

Yan Song

2580